此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

HEC-151 注射液单次递增剂量研究

2026年9月24日 更新者:Sunshine Lake Pharma Co., Ltd.

一项I期临床试验,在中国健康受试者中单中心、随机、安慰剂(单盲)和阳性对照(开放标签)研究中评估单剂量HEC-151注射液的安全性、耐受性、药代动力学/药效学特征

Evaluate the safety, tolerability, PK/PD and immunogenicity characteristics of a single subcutaneous HEC-151 Injection solution in healthy participants

研究概览

研究类型

介入性

注册 (估计的)

81

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Chengyong Tang, Doctor
  • 电话号码:+8618983286980
  • 邮箱:17235387@qq.com

学习地点

    • Bishan
      • Chongqing、Bishan、中国、402760
        • 招聘中
        • No. 9, Shuangxing Avenue,, Bishan
        • 接触:
          • Chengyong Tang, Doctor
          • 电话号码:8618983286980
          • 邮箱:17235387@qq.com
    • Chongqing Municipality
      • Bishan、Chongqing Municipality、中国、402760
        • 尚未招聘
        • No. 9, Shuangxing Avenue,
        • 接触:
          • Chengyong Tang, Doctor
          • 电话号码:+8618983286980
          • 邮箱:17235387@qq.com

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 45年 (成人)

接受健康志愿者

是的

有资格学习的性别

男性

描述

Inclusion Criteria:

  1. Voluntarily participate in the trial and sign the informed consent form, understanding and abiding by the research procedures;
  2. When signing the informed consent form, men aged 18-45 years old (including the boundary value) are eligible;
  3. During the screening process, male subjects with a body weight of ≥ 50 kg and a body mass index (BMI) of ≥ 19.0 and ≤ 24.0 kg/m2 are included;
  4. Normal glucose tolerance [3.9 mmol/L < fasting blood glucose (FPG) < 6.1 mmol/L, and 2-hour post-glucose tolerance test (OGTT) blood glucose after sugar intake < 7.8 mmol/L];
  5. Normal results of insulin release test (IRT), or abnormal results but judged by the researcher to have no clinical significance;
  6. Glycated hemoglobin (HbA1c) < 5.7%;
  7. During the study period, there are no plans for reproduction, sperm collection, or sperm donation, and are willing to take effective contraceptive measures throughout the study period until 3 months after the administration of the investigational drug.

Exclusion Criteria:

  1. Participants with abnormal medical histories or surgical histories judged clinically significant by the researchers, or currently suffering from any diseases in the endocrine system, blood system, cardiovascular system, respiratory system, digestive system, urinary system, immune system, nervous system, etc. that are judged clinically significant by the researchers, or any other diseases or physiological conditions that can significantly affect the absorption, distribution, metabolism or excretion of the drugs;
  2. Participants who have a known severe allergic history or are allergic to the test drugs and any of their components;
  3. Participants who had severe trauma or undergone surgery within 90 days before the screening, or plan to undergo major surgery during the study;
  4. Participants who have a history of hypoglycemia or hyperglycemia within 90 days before the screening, or have a family history of diabetes (first-degree direct relatives);
  5. Participants who have donated blood or suffered significant blood loss (≥ 400 mL) within 90 days before the screening, or plan to donate blood during the study;
  6. Participants who have acute diseases or concurrent medication use from the signing of the informed consent form to the first administration of the drug;
  7. Participants whose vital signs, physical examination, laboratory tests, electrocardiogram, chest X-ray examination, etc. results are abnormal and judged by the researchers to have clinical significance;
  8. Participants whose test results for hepatitis B surface antigen (HBsAg), hepatitis C antibody (anti-HCV), combined human immunodeficiency virus antigen antibody (HIV), or syphilis spirochete antibody (TP) are positive;
  9. Participants who have a history of drug abuse or drug use, or whose urine drug screening is positive before the screening;
  10. Participants who have used any prescription drugs, Chinese herbal medicines, over-the-counter drugs, health supplements (except for regular supplementary vitamins and calcium) within 30 days before the screening;
  11. Participants who have participated in any clinical research of drugs or devices (defined as receiving the test drugs or devices) within 90 days before the screening;
  12. Participants who have received any vaccine within 30 days before the screening, or plan to receive any type of vaccine during the study;
  13. Participants who smoke more than 5 cigarettes per day within 90 days before the screening, or cannot comply with the smoking prohibition rule during the study;
  14. Participants who frequently drink alcohol, that is, consuming more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% alcohol spirits or 150 mL of wine), or have a positive alcohol breath test; or who cannot comply with the alcohol prohibition rule during the study;
  15. Participants who consume excessive tea, coffee and/or caffeine-rich beverages (more than 8 cups, 1 cup ≈ 250 mL) or food (such as chocolate) every day within 90 days before the screening, or during the study;
  16. Participants who have used special diets (including dragon fruit, mango, pomelo, etc.) and/or xanthine diet (salmon, sardines, liver, kidney, etc.) or have other factors affecting drug absorption, distribution, metabolism, and excretion before the signing of the informed consent form to the use of the test drugs, or who cannot comply with the prohibition of eating during the study;
  17. Participants who have had significant changes in diet or exercise habits within 90 days before the screening, or have engaged in intense exercise before the signing of the informed consent form to the use of the test drugs, or cannot stop during the study;
  18. Participants who have difficulty in venous blood collection, or cannot tolerate venipuncture, or have a history of fainting or hematemesis;
  19. Participants who, in the researcher's opinion, have other factors that are not suitable for participating in this study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:HEC-151 Injection

The participants received an abdominal subcutaneous HEC-151 Injection in the morning of Day 1.

Subcutaneous injection in the abdominal area

有源比较器:Insulin Degludec

The participants received an abdominal subcutaneous injection of Insulin Degludec in the morning of Day 1.

Subcutaneous injection in the abdominal area

安慰剂比较:Placebo

The participants received an abdominal subcutaneous Injection of placebo in the morning of Day 1.

Subcutaneous injection in the abdominal area

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Adverse event
大体时间:From Day1 to Day36

Frequency, type and severity of adverse events/serious adverse events.

From Day1 to Day36
Electrocardiogram parameter(Heart rate)
大体时间:From Day1 to Day36

Evaluation the heart rate of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36
Electrocardiogram parameter(PR interval)
大体时间:From Day1 to Day36

Evaluation the PR interval of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36
Electrocardiogram parameter(QTcF interval)
大体时间:From Day1 to Day36

Evaluation the QTcF interval of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36
Electrocardiogram parameter(QRS interval)
大体时间:From Day1 to Day36

Evaluation the QRS interval of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36
Vital signs parameter(Body temperature)
大体时间:From Day1 to Day36

Evaluation the body temperature of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36
Vital signs parameter(Blood pressure)
大体时间:From Day1 to Day36

Evaluation the blood pressure of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36
Vital signs parameter(Pulse)
大体时间:From Day1 to Day36

Evaluation the pulse of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36
Vital signs parameter(Respiration)
大体时间:From Day1 to Day36

Evaluation the respiration of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36

次要结果测量

结果测量
措施说明
大体时间
Cmax
大体时间:From Day1 to Day36

Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
AUC0-t
大体时间:From Day1 to Day36

Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
Tmax
大体时间:From Day1 to Day36

Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
T1/2
大体时间:From Day1 to Day36

Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
CL/F
大体时间:From Day1 to Day36

Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
GIRmax
大体时间:From Day1 to Day36

Evaluate the Pharmacodynamics effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
tGIRmax
大体时间:From Day1 to Day36

Evaluate the Pharmacodynamics effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
AUCGIR
大体时间:From Day1 to Day36

Evaluate the Pharmacodynamics effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
ADA(Anti-Drug Antibody)
大体时间:From Day1 to Day36

Evaluate the Immunogenic characteristics of HEC-151 Injection in healthy participants.

From Day1 to Day36

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年2月24日

初级完成 (估计的)

2026年12月31日

研究完成 (估计的)

2027年1月31日

研究注册日期

首次提交

2026年1月14日

首先提交符合 QC 标准的

2026年1月21日

首次发布 (实际的)

2026年1月29日

研究记录更新

最后更新发布 (实际的)

2026年9月25日

上次提交的符合 QC 标准的更新

2026年9月24日

最后验证

2026年1月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • HEC-151-DM-101

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅